The FDA is delaying a decision on whether to approve a drug for preventing infection with HIV, for 3 more months.
FDA delays decision on drug to prevent HIV - The Washington Post:
"In May, a committee of FDA advisers recommended that the agency approve Truvada for HIV prevention in specific high-risk groups, including men who have sex with men and partners of those infected with HIV.
After that meeting, the FDA asked Gilead to revise its risk-management plan for the drug, Miller said.
She declined to provide details on how Gilead revised this plan, which is known as a risk evaluation and management strategy."
'via Blog this'
If approved, Truvada would become the first drug marketed for prevention of HIV. The FDA will now make a decision by Sept. 14.
Return Home: The Health, Drug, Prescription, and GMP Supersite Blog
SkillsPlus Intl Inc. - GMP and QSR Compliance Training Experts
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store
Workplace Burnout: Lessons From Professional Cycling
28 minutes ago
No comments:
Post a Comment